Aclarion adds NYU Langone Health as clinical site for CLARITY trial of Nociscan in chronic low back pain
ACON•Aclarion added NYU Langone Health as an enrolling site for its 300-patient CLARITY trial of Nociscan in spine surgery; the ongoing study will assess outcomes at 12 months, and no results have been presented.
1. Trial site added
Aclarion added NYU Langone Health as an enrolling site for its CLARITY randomized trial evaluating Nociscan in spine surgery. The trial targets 300 patients across multiple centers and aims to assess whether Nociscan can improve surgical outcomes by better identifying pain-generating discs; outcomes will be assessed at 12 months.
